Q1 2024 EPS Estimates for Tyra Biosciences, Inc. (NASDAQ:TYRA) Reduced by Wedbush

Tyra Biosciences, Inc. (NASDAQ:TYRAFree Report) – Equities research analysts at Wedbush lowered their Q1 2024 earnings per share estimates for shares of Tyra Biosciences in a research note issued to investors on Wednesday, March 20th. Wedbush analyst R. Driscoll now expects that the company will post earnings per share of ($0.45) for the quarter, down from their prior estimate of ($0.37). Wedbush has a “Outperform” rating and a $28.00 price objective on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($1.95) per share. Wedbush also issued estimates for Tyra Biosciences’ Q2 2024 earnings at ($0.47) EPS, Q3 2024 earnings at ($0.51) EPS, Q4 2024 earnings at ($0.50) EPS, FY2024 earnings at ($1.93) EPS, FY2025 earnings at ($2.22) EPS, FY2026 earnings at ($2.49) EPS, FY2027 earnings at ($2.54) EPS and FY2028 earnings at ($1.81) EPS.

TYRA has been the subject of several other reports. Bank of America lowered Tyra Biosciences from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $25.00 to $15.00 in a research note on Friday, December 15th. HC Wainwright reissued a “buy” rating and issued a $23.00 target price (up previously from $19.00) on shares of Tyra Biosciences in a research note on Wednesday, March 20th.

View Our Latest Research Report on Tyra Biosciences

Tyra Biosciences Stock Down 1.5 %

NASDAQ:TYRA opened at $16.47 on Monday. The company has a market cap of $865.00 million, a P/E ratio of -10.23 and a beta of 1.19. The firm’s 50 day moving average is $17.16 and its two-hundred day moving average is $14.56. Tyra Biosciences has a fifty-two week low of $10.38 and a fifty-two week high of $20.67.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TYRA. Kynam Capital Management LP bought a new position in shares of Tyra Biosciences during the fourth quarter worth about $4,712,000. JPMorgan Chase & Co. lifted its holdings in Tyra Biosciences by 119.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 423,421 shares of the company’s stock worth $7,211,000 after buying an additional 230,912 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Tyra Biosciences by 33.6% in the 2nd quarter. BlackRock Inc. now owns 890,832 shares of the company’s stock valued at $15,171,000 after acquiring an additional 223,947 shares during the last quarter. Vanguard Group Inc. increased its stake in Tyra Biosciences by 12.9% during the third quarter. Vanguard Group Inc. now owns 732,584 shares of the company’s stock valued at $10,088,000 after purchasing an additional 83,709 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Tyra Biosciences by 55.5% during the first quarter. State Street Corp now owns 203,680 shares of the company’s stock worth $2,179,000 after purchasing an additional 72,670 shares during the period. 84.14% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, COO Daniel Bensen sold 1,501 shares of Tyra Biosciences stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $20.00, for a total transaction of $30,020.00. Following the sale, the chief operating officer now directly owns 451,480 shares of the company’s stock, valued at $9,029,600. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold 15,816 shares of company stock valued at $298,165 in the last quarter. Company insiders own 18.40% of the company’s stock.

Tyra Biosciences Company Profile

(Get Free Report)

Tyra Biosciences, Inc, a clinical-stage biotechnology company, focuses on developing next-generation precision medicines for fibroblast growth factor receptor (FGFR) biology. The company offers SNÅP, an in-house precision medicine platform which precise drug design through iterative molecular snapshots to predict genetic alterations for developing oncology and genetically defined condition therapies.

Recommended Stories

Earnings History and Estimates for Tyra Biosciences (NASDAQ:TYRA)

Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.